Veracyte (VCYT) Valuation Check After Strong 2025 Earnings And Reaffirmed 2026 Growth Outlook [Yahoo! Finance]
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Yahoo! Finance
Veracyte (VCYT) just delivered fourth quarter and full year 2025 results that combined higher revenue with much stronger profitability, while also reaffirming its 2026 guidance for double digit growth tied to its cancer testing portfolio. See our latest analysis for Veracyte. Even with the strong 2025 earnings and reaffirmed 2026 outlook, Veracyte's recent share price performance has been weak in the short term, with a 30 day share price return of 5.44% and a 90 day share price return of 21.99%. Longer term total shareholder return over 1 year is 7.30% and 3 year total shareholder return is 51.75%, suggesting earlier optimism is being reassessed after a strong multi year run. If this earnings news has you looking across cancer and AI focused diagnostics, it could be a good moment to survey 28 healthcare AI stocks as potential additions to your watchlist. With Veracyte now profitable, guiding for double digit revenue growth in 2026 and trading at a discount to the average anal
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening [Yahoo! Finance]Yahoo! Finance
- Veracyte (VCYT) had its price target raised by Needham & Company LLC from $44.00 to $48.00. They now have a "buy" rating on the stock.MarketBeat
- Veracyte Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Veracyte outlines 10%–13% revenue growth for 2026 while advancing MRD and Prosigna launches [Seeking Alpha]Seeking Alpha
- Veracyte (VCYT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
VCYT
Earnings
- 2/25/26 - Beat
VCYT
Sec Filings
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- VCYT's page on the SEC website